Florian Guisier

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier et al. · The Lancet Oncology · 2019 · 458 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Myriam Delaunay, J. Cadranel, Amélie Lusque et al. · European Respiratory Journal · 2017 · 421 citations · Full text

Medicine, Immunology, Oncology +15

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

Alice Tison, Gilles Quéré, L. Misery et al. · Arthritis & Rheumatology · 2019 · 312 citations · Full text

Life Sciences, Immunology, Oncology +16

Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018

Florian Guisier, Catherine Dubos‐Arvis, F. Viñas et al. · Journal of Thoracic Oncology · 2020 · 296 citations · Full text

Medicine, Molecular Medicine, Oncology +17

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette et al. · Journal of Thoracic Oncology · 2019 · 182 citations · Full text

Medicine, Oncology, Pharmacology +15